Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Makes it hard to read the EMA or SMA whatever you use.
The VNDA CEO did an interview yesterday with Fox business. The FDA gave them a call the afternoon before and said we changed our evaluation of your drug and are giving you approval. He said they were like wow.
You are right it was not this kind of volume. Anyone else have their chart just get manipulated. Had a buy come through at .138, shrunk the chart. Don't know what to make of that, if they want to buy mine are available. Just do not make my chart harder to read. I was just looking at .014's going through ten minutes ago. Strange.
It was unbelievable. Caught the interview from the CEO on Fox and they had been completely blind-sided by the call.
It was unbelievable. Caught the interview from the CEO on Fox and they had been completely blind-sided by the call.
Never know. It was last time too. I will just leverage my position on Monday with a little sale.
I hope you are right though.
Lets hope they get a call just like VNDA received.
And that surprises you Surfmore. I think some people need to eat some crow.
Waiting till Monday. Will continue to rise off speculation. MM trying to hold it with a couple shakes. They are running low. Then will cash %50 out monday for a 200% plus gain, knock on wood.
This place is funny.
The same people telling you all they are BK and Sell now are being asked for advice. LOL
How many here are running two screen names.
The train already left. Buying at .005's selling half now riding free and protected going into the meeting. Same thing over and over and over.
Move is off of speculation on the meeting.
Sorry can't send private messages. What region you working in? I don't work anymore doing that. My brother does though.
If we have a partner I am thinking .10 minimum till approval.
If the R/S goes through we are still ok in my eyes. The 2009 note holders have a dilution protection provision in it for themselves. Which in a way helps us but the R/S would just decrease our gains.
R/S voted down .05 to .10
Approval could be anywhere from .20 to 1.00 in my opinion.
All due to the how bad people want in and what our existing O/S is at that time.
Just my opinion factoring in all the data I can, others have theirs too. Personally I am not worried. This is not a normal penny stock. Lately I have used other cancer Biotechs for market cap valuation and that is even sketchy, due to Genasense being a big break through. If approved.
Anyway, I am not an expert.
Hey John I think you missed my favorite one.
The one about them getting the body to drastically improve uptake of Genasense to where it needs to go.
http://www.ncbi.nlm.nih.gov/pubmed/19183107?ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Don't worry. If we do not get some fantastic news on the CC then he will be back.
Yes it was approved. After being told to get more information. Does this sound familiar. They did not do another trial. The CEO was just on Fox Business doing an interview. And they found out last night that the FDA changed their mind!
Just thinking positive. Hoping.
No, due to the indications of Genasense being approved would put it IMHO around $1. No kiddin. 2-3 billion market cap is what I am estimating.
Vanda Pharmaceuticals Inc. (VNDA, $7.80, +$6.72, +622.22%) shares soared following FDA approval of its schizophrenia drug Fanapt. The move comes as a surprise because the FDA rejected the drug last summer and asked for more data on multiple fronts, causing VNDA to respond with its arguments about the drug's usefulness to patients. "The agency did a complete about face," said Natixis Bleichroeder, which reinstated its buy rating with a $12 price target. But the firm noted that the company must now figure out how to sell the drug by either finding a partner, or attempting to raise money.
Wonder if this could happen to Genasense. Lets hope this is a good sign of new management at the agency.
No kiddin.
We must be really stupid.
I do too.
I liked the direction I heard on the conference call. I-phone, toyota etc.
Plus with the economy possibly starting a slow turn.
No fall off on earnings. Sure they did not meet the estimate, but -.02 in todays market as an estimate was nutz.
Liberty involved.
I like the outlook.
May be hitting some stop losses.
To me if you dig deep into the financials, with the current market on this business the results are promising. Others I guess disagree.
Can someone explain preferred beneficial stock conversion?
Specifically how it is being calculated into the accounting.
The way I understand it is it is the difference between conversion and current share price. So it is a way of calculating a loss to the shareholder by the preferred being in the money. But it is not really a true loss to the company and is more of a gray area of how one views it in the big picture.
LOL Boy this is rich. You guys jump all over people who are saying the same as you but against the R/S. You tell everyone how screwed they are in the financial arrangement before April 1. I wonder, maybe to make people sell. You guys sure your not in with the 2009 note holders.
They may and if they do that is fine. Guys long story short and we are on the same page. Reread.
This gives us all an understanding of where they are and is a good measuring stick.
It could mean:
Early approval.
Better financial arrangement.
Partner
And more.
This can give them some good leverage.
I know read my posts. LOL
Do some more DD. The DMB can stop the trial in its tracks, give the thumbs up or tell them to stop and submit for approval. This will be the FINAL meeting of the DMB on this trial.
If you do some reading on the EMEA and this trial. It is stating that if they can back up the results with this trial they would very much consider approval. Now I am not pumping the stock. Do your own DD on the EMEA and Genta.
This final DMB meeting is big.
Basically it will give us a good insight into how the trial is going. And hopefully they say they can end it early, since this is a priority drug.
Is this big PR in reference to the DMB?
Last post for the day.
Looking from the trading range a low .006 to mid .005 looks to be a good position to enter at. Although we all know that can change at any time.
That is correct. For me the risk on this one is worth it to me. Everyone has to make up their own mind.
Unfortunately it does continue because shareholders buy into it, when in reality it is from a business perspective poor management decisions. Case in point is Ganite, I mentioned that yesterday. Now alot of biotechs have to issue additional shares to finance R/D when up and coming. Genta's position if they are being managed right in my opinion should not be coming to this.
People need to learn what rights they have as a shareholder instead of letting others tell you stories.
They need the 2009 note holders to give the go ahead if they want to go above 1/50. Everyone slow down and try to read more carefully.
Post 11961. Do you really want me to go get the other ones. They are worse than this.
Very well stated. I am just putting that perspective out there, so others that have not considered it do so.
I still think the best option is to bring on a marketing and distribution partner asap. Not only will it provide an immediate infusion of capital, we will not be heavily diluted and it will give the company more name recognition on the stock. Last it would not hurt to have some more leverage going back into the approvals process.
Long story short, we are racing against the clock to get this to market. Sometimes the best option is to give a portion of the pie to someone else and move on with the rest of the pipeline. They need to start producing positive cash flow.
"They'll reverse split whether or not the voters vote yes or no."
Not without shareholders authorizing it. They have to get approval from the shareholders (company owners) thus the reason to vote on it.
This is getting more and more desperate, say hi to the note holders for me.
Don't mind him. He was telling everyone to bail out months ago because they are going to file for BK.
People bash not only to short. If I was a 2009 note holder knowing GNTA's potential I would do what I could to get people to sell before April 1. And then let the stock run. That way I can convert the max allowable shares.
Also they only enter default if they do not do a R/S 105 days from the initial closing. So if the R/S vote was no, they still more time than 20 days.
This is a chance for shareholders to voice their opinion on the financing. There are better deals out there to be had for shareholders (company owners). This to me is the reason why you want seperation of your board and company management. Not saying that they are horrible, but having your CEO as your Chairman is a conflict of interest.
There was a bunch saying on here a month ago too. Around April 1. I wonder why. Now people are trying to convince others to vote yes for a R/S. Am I the only one who can see the pattern.
Does anyone know when this interview was given?
The partnership or other financing is what I am banking on. Either way if you entered correctly you will get your money and then some. We will see.
Does not make much sense does it. Remember they have 105 days from initial closing to effect a R/S. So they need to be shopping for a better deal in my opinion.
Ok so let me get this straight. They are harnessing an Transferrin conjugated to lipopolyplexes to more effectively carry the Genasense compound into the cancer tissue. And this uptake of the conjugated compound is a immune response with the tumor.
Never mind found it. Kind of off on that.